CAS: 335621-00-6
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | 9-Oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid,1,1-dimethylethyl ester, hydrochloride (1:1)OTHER CA INDEX NAMES:9-Oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid,1,1-dimethylethyl ester, monohydrochloride REF: IN-DA00IKMOCAS: 335621-00-6 | 97% | To inquire | Thu 13 Feb 25 |
 | 3-BOC-9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE HCL REF: 10-F468134CAS: 335621-00-6 | 97% | - - - | Discontinued product |
 | 3-boc-9-oxa-3,7-diazabicyclo[3.3.1]nonane hcl REF: 3D-KNA62100CAS: 335621-00-6 | Min. 95% | - - - | Discontinued product |
![9-Oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid,1,1-dimethylethyl ester, hydrochloride (1:1)…](https://static.cymitquimica.com/products/IN/thumb/DA00IKMO.jpg)
9-Oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid,1,1-dimethylethyl ester, hydrochloride (1:1)OTHER CA INDEX NAMES:9-Oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid,1,1-dimethylethyl ester, monohydrochloride
CAS:335621-00-6
Formula:
C11H21ClN2O3
Purity:
97%
Color and Shape:
Solid
Molecular weight:
264.7490
Ref: IN-DA00IKMO
| 100mg | 531.00 € | ||
| 250mg | 598.00 € | ||
| 500mg | To inquire |
Estimated delivery in United States, on Thursday 13 Feb 2025
![3-BOC-9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE HCL](https://static.cymitquimica.com/products/10/thumb/F468134.jpg)
Ref: 10-F468134
| 1g | Discontinued | Request information | |
| 100mg | Discontinued | Request information | |
| 250mg | Discontinued | Request information |
![3-boc-9-oxa-3,7-diazabicyclo[3.3.1]nonane hcl](https://static.cymitquimica.com/products/3D/thumb/KNA62100.jpg)
3-boc-9-oxa-3,7-diazabicyclo[3.3.1]nonane hcl
CAS:335621-00-6
Versatile small molecule scaffold
Formula:
C11H21ClN2O3
Purity:
Min. 95%
Molecular weight:
264.75 g/mol
Ref: 3D-KNA62100
| 25mg | Discontinued | Request information | |
| 50mg | Discontinued | Request information | |
| 100mg | Discontinued | Request information | |
| 250mg | Discontinued | Request information | |
| 500mg | Discontinued | Request information |
